Gilead Sciences, Inc. $GILD Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,593,538 shares of the biopharmaceutical company’s stock after selling 352,428 shares during the quarter. ProShare Advisors LLC owned approximately 0.13% of Gilead Sciences worth $176,883,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. GoalVest Advisory LLC grew its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences during the 3rd quarter valued at approximately $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the 2nd quarter worth $27,000. Putney Financial Group LLC increased its position in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the period. Finally, Howard Hughes Medical Institute bought a new stake in Gilead Sciences in the second quarter valued at $30,000. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GILD shares. Scotiabank initiated coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target on the stock. Citigroup raised their target price on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Leerink Partners raised their price target on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a report on Friday, January 30th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the insider directly owned 103,221 shares of the company’s stock, valued at $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 373,037 shares of company stock worth $50,731,512 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 2.1%

NASDAQ:GILD opened at $152.50 on Monday. The business’s fifty day moving average price is $127.38 and its 200 day moving average price is $121.04. The firm has a market capitalization of $189.20 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.80 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $153.13.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.